Nyrada (ASX:NYR) Advances NYR-BI03 Drug with Successful Safety Study

2 min read | October 07, 2024 12:05 PM AEDT | By Team Kalkine Media

Google News:

Nyrada (ASX:NYR) Advances NYR-BI03 Drug with Successful Safety Study — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Nyrada completed a safety study for its NYR-BI03 drug candidate.

The drug is being developed to treat stroke and traumatic brain injury (TBI).

Phase 1 human trials are expected to begin by late 2024.

Sydney-based Nyrada Inc (ASX:NYR) has taken a significant step forward in its drug development efforts. The company recently completed an in vivo micronucleus study on rats, which confirmed the safety of its NYR-BI03 drug candidate. This study, involving an ASX healthcare stock, focuses on ensuring no genetic damage and paves the way for Phase 1 human trials later this year.

Promising Results for Stroke and TBI Treatment

The NYR-BI03 drug is being developed to treat both stroke and traumatic brain injury (TBI). Earlier this year, a preclinical stroke study revealed the drug’s potential by achieving a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals. These findings build optimism for its future development.

Broader Potential in Cardioprotection

In addition to its neuroprotective properties, NYR-BI03 has shown promise in cardiovascular health. A preclinical study in October demonstrated that the drug achieved an 86% cardioprotection effect following myocardial ischemia-reperfusion injury. This result was also statistically significant, suggesting that NYR-BI03 may have broader applications beyond stroke and brain injury.

Looking Ahead: Human Trials

With the completion of these Good Laboratory Practices (GLP) studies, Nyrada plans to submit a Human Research Ethics Application. This submission is a crucial step toward initiating the first Phase 1 human trials, which are expected to begin in late 2024.

Nyrada's progress in developing NYR-BI03 is generating attention, and with shares trading around 10 cents, the company is positioned for continued momentum as it advances its research and development efforts.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.